Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
MiNK Therapeutics announced promising results for its allogeneic iNKT cell therapy, agenT-797, showcasing early clinical activity in solid tumors with 27% of patients achieving disease stabilization alone and 66% in combination with pembrolizumab or nivolumab. Noteworthy is the survival benefit observed in viral ARDS patients, with a 70% survival rate versus 10% in controls. Moreover, agenT-797 demonstrated a favorable safety profile with no cytokine release syndrome reported, and the company is advancing new candidates for next-generation CAR-iNKT therapies.
MiNK Therapeutics reported third-quarter 2022 financial results, highlighting a net loss of $6.3 million ($0.19 per share), a significant reduction from a net loss of $14.3 million ($0.59 per share) in Q3 2021. The company had a cash balance of $24.2 million as of September 30, 2022, down from $38.9 million at the end of 2021. Operational cash usage increased, reflecting the internalization of cGMP manufacturing for clinical trials. The firm will present at the Society of Cancer Immunotherapy Meeting, showcasing clinical data on its iNKT cell therapies.
MiNK Therapeutics will release its third quarter 2022 financial results on November 3rd, 2022, before the market opens. A conference call is scheduled for 8:30 a.m. ET the same day, providing insights into the company's progress in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
The company focuses on scalable and reproducible manufacturing methods for its therapies, aiming for off-the-shelf delivery to patients.
MiNK Therapeutics is set to host a Research & Development Day on November 10, 2022, from 4:00 to 6:00 PM ET in Boston, MA, and via webcast. The event will highlight the company’s novel allogeneic iNKT cell therapy platform and feature insights from clinical trials and next-gen programs. Presentations will cover initial data from a phase 1 trial of iNKTs with anti-PD-1 inhibitors, as well as advancements in the FAP-CAR-iNKT program. The event will include leading immuno-oncology experts and is open to institutional investors.
MiNK Therapeutics announced the acceptance of five abstracts at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, scheduled for November 8-12, 2022. These abstracts focus on clinical data for AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy targeting advanced solid tumors, viral ARDS, and refractory multiple myeloma. New therapeutic candidates, MiNK-215 and MiNK-413, are also highlighted, showcasing advancements in CAR-iNKT therapy. The meeting will feature presentations from several experts, emphasizing the company's commitment to innovative cancer treatments.
MiNK Therapeutics, a biopharmaceutical firm focused on allogeneic iNKT cell therapies for cancer and immune diseases, will participate in two investor conferences this September. The HC Wainwright 24th Annual Global Investment Conference will feature a webcast on September 12th at 7:00 AM ET. Additionally, MiNK will participate in the Baird 2022 Global Healthcare Conference on September 14th at 1:25 PM ET. Both events will allow investors to explore MiNK's innovative therapies. Webcast replays will be available on the Company’s website.
MiNK Therapeutics reported its Q2 2022 financial results, highlighting ongoing advancements in its clinical programs, particularly AgenT-797 for cancer and viral ARDS. The company completed internal cGMP production capable of treating over 700,000 patients annually. Clinical data updates for AgenT-797 and a novel stromal-CAR-iNKT program are anticipated in the second half of 2022. Financially, MiNK ended Q2 with $29.8 million in cash and reported a net loss of $6.1 million, slightly improving from the previous year. The leadership team has also been expanded, notably appointing Dr. Joy Zhou as VP of CMC.
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference. The company will participate virtually and conduct one-on-one meetings with investors on August 8th and 9th. MiNK is advancing both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery. For more details, visit their website at minktherapeutics.com.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its Q2 2022 financial results prior to the market opening on August 9, 2022. A conference call is scheduled for 11:00 a.m. ET on the same day to discuss the results and provide corporate updates. MiNK specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases, with a focus on scalable and reproducible manufacturing.
MiNK Therapeutics, a biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies, announced its virtual Annual Meeting of Shareholders set for June 8, 2022, at 5:00 PM ET. Shareholders can join via a dedicated website using a control number from proxy materials, while guests can listen without a control number. The company aims to advance its pipeline of iNKT programs targeting cancer and immune-mediated diseases, with scalable and reproducible manufacturing processes.